Anti-PD1 antibody: a new approach to treatment of lymphomas

被引：32
|
作者：
Bachy, Emmanuel [1 ,2 ,3 ]
Coiffier, Bertrand [1 ,2 ,3 ]
机构：
[1] Hosp Civils Lyon, Dept Hematol, Lyon, France
[2] Univ Lyon 1, Dept Hematol, F-69365 Lyon, France
[3] Ctr Hosp Lyon Sud, F-69310 Pierre Benite, France
来源：
LANCET ONCOLOGY | 2014年 / 15卷 / 01期
关键词：
FOLLICULAR LYMPHOMA; T-CELLS; PD-1;
D O I：
10.1016/S1470-2045(13)70587-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：7 / 8
页数：2
相关论文
共 50 条
  • [31] Fulminant Type 1 Diabetes Mellitus Accompanied by Positive Conversion of Anti-insulin Antibody after the Administration of Anti-CTLA-4 Antibody Following the Discontinuation of Anti-PD-1 Antibody
    Shiba, Michiru
    Inaba, Hidefumi
    Ariyasu, Hiroyuki
    Kawai, Shintaro
    Inagaki, Yuko
    Matsuno, Shohei
    Iwakura, Hiroshi
    Yamamoto, Yuki
    Nishi, Masahiro
    Akamizu, Takashi
    INTERNAL MEDICINE, 2018, 57 (14) : 2029 - 2034
  • [32] Immunity reloaded: Deconstruction of the PD-1 axis in B cell lymphomas
    Bednarska, Karolina
    Nath, Karthik
    Nicol, William
    Gandhi, Maher K.
    BLOOD REVIEWS, 2021, 50
  • [33] Thiazolidinedione enhances the efficacy of anti-PD-1 monoclonal antibody in murine melanoma
    Zhang, Xinyi
    Gao, Yuan
    Tang, Keyun
    Li, Zongyu
    Halberstam, Alexandra A.
    Zhou, Liqun
    Perry, Rachel J.
    AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2024, 326 (03): : E341 - E350
  • [34] Epitope characterization of an anti-PD-L1 antibody using orthogonal approaches
    Hao, Gang
    Wesolowski, John S.
    Jiang, Xuliang
    Lauder, Scott
    Sood, Vanita D.
    JOURNAL OF MOLECULAR RECOGNITION, 2015, 28 (04) : 269 - 276
  • [35] Retrospective Analysis of Adoptive TIL Therapy plus Anti-PD1 Therapy in Patients with Chemotherapy-Resistant Metastatic Osteosarcoma
    Zhou, Xiang
    Wu, Junlong
    Duan, Chunguang
    Liu, Yingjie
    JOURNAL OF IMMUNOLOGY RESEARCH, 2020, 2020
  • [36] Combination chemotherapeutic and immune-therapeutic anticancer approach via anti-PD-L1 antibody conjugated albumin nanoparticles
    Pham, Le Minh
    Poudel, Kishwor
    Ou, Wenquan
    Phung, Cao Dai
    Nguyen, Hanh Thuy
    Nguyen, Bao Loc
    Karmacharya, Prajeena
    Pandit, Mahesh
    Chang, Jae-Hoon
    Jeong, Jee-Heon
    Ku, Sae Kwang
    Yong, Chul Soon
    Choi, Han-Gon
    Kim, Jong Oh
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2021, 605
  • [37] MAIT cells confer resistance to Lenvatinib plus anti-PD1 antibodies in hepatocellular carcinoma through TNF-TNFRSF1B pathway
    Zhou, Cheng
    Sun, Bao-Ye
    Zhou, Pei-yun
    Yang, Zhang-Fu
    Wang, Zhu-Tao
    Liu, Gao
    Gan, Wei
    Wang, Zheng
    Zhou, Jian
    Fan, Jia
    Yi, Yong
    Ren, Ning
    Qiu, Shuang-Jian
    CLINICAL IMMUNOLOGY, 2023, 256
  • [38] Optimal timing of anti-PD-1 antibody combined with chemotherapy administration in patients with NSCLC
    Huo, Yachang
    Wang, Dan
    Yang, Shuangning
    Xu, Yujie
    Qin, Guohui
    Zhao, Chenhui
    Lei, Qingyang
    Zhao, Qitai
    Liu, Yaqing
    Guo, Kaiyuan
    Ouyang, Songyun
    Sun, Ting
    Wang, Hongmin
    Fan, Feifei
    Han, Na
    Liu, Hong
    Chen, Hongjie
    Miao, Lijun
    Liu, Li
    Duan, Yuqing
    Lv, Wei
    Liu, Lihua
    Zhang, Zhixin
    Cang, Shundong
    Wang, Liping
    Zhang, Yi
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (12)
  • [39] Expression of PD-1/PD-L1 in children's classical Hodgkin lymphomas
    Dilly-Feldis, Marie
    Aladjidi, Nathalie
    Refait, John K.
    Parrens, Marie
    Ducassou, Stephane
    Rullier, Anne
    PEDIATRIC BLOOD & CANCER, 2019, 66 (05)
  • [40] PD-1 expression and clinical PD-1 blockade in B-cell lymphomas
    Xu-Monette, Zijun Y.
    Zhou, Jianfeng
    Young, Ken H.
    BLOOD, 2018, 131 (01) : 68 - 83
12345